Recombinant KLK1: the next step in stroke and preeclampsia treatment
With its lead candidate DM199, DiaMedica Therapeutics is advancing a recombinant form of KLK1 to res...
251 Ballardvale Street,
Wilmington,
MA 01887United States
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.
With its lead candidate DM199, DiaMedica Therapeutics is advancing a recombinant form of KLK1 to res...
New research has discovered a key survival mechanism in metastatic melanoma, revealing that cancer c...
Researchers have discovered that pancreatic tumours evade the immune system by disguising themselves...
Unlock Exclusive Industry Insights